Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.

Revenue
−10.1%
EPS
−36.8%
Free cash flow
−70.5%
Total debt
+14.1%

Quarter to September 2026, against a year earlier

14.53 0.24 −1.62%
Market cap
$12.1B
P/E
44.4×
Fwd P/E
30.7×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100

Dr. Reddy's Laboratories Ltd (RDY) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a EV/FCF of 126×. Over the past ten years it has ranged from −42.6× (November 2016) to 562× (October 2024); the current reading is higher than 95% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2026 53.1× (23.16%)
FY2025 69.1× 37.40%
FY2024 50.3× 176.66%
FY2023 18.2× (67.38%)
FY2022 55.7× 74.80%
FY2021 31.9× 53.99%
FY2020 20.7× (3.06%)
FY2019 21.4× (60.04%)
FY2018 53.5× —
FY2017 −24.0× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 109× 34.69%
Jun 2026 80.9× 52.38%
Mar 2026 53.1× 32.72%
Dec 2025 40.0× (23.55%)
43 more quarters

Against its own ten years

Low −42.6× High 562×
Ten-year median 34.6×
Current reading's percentile 94

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on RDY